September 23-25, Switzerland

Free Registration, Part of MipTec 2014, Congress Center Basel

FREE DRUG DISCOVERY CONFERENCE IN THE HEART OF EUROPE

MipTec is the largest drug discovery conference in Europe with over 3,000 delegates from pharmaceutical companies

ATTEND 10 OTHER SCIENTIFIC FORUMS AT MIPTEC

Stem Sells, Translational Medicine, Protein Therapeutics, Medicinal Chemistry and others

IN SILICO APPROACHES TO GEROPROTECTOR DISCOVERY AND DRUG REPURPOSING

New in silico approaches to evaluating the efficacy of and repurposing drugs for aging and age-related diseases

MEET YOUNG PROSPECTIVE SCIENTISTS AND RESEARCH MANAGERS

The forum will attract many young scientists in aging research providing the possibility to recruit scarse talent with unique skills and interests

AGING CONFERENCE FOCUSED ON REINVENTINT THE PHARMA INDUSTRY

Unlike other aging conferences, the forum is geared towards the pharmaceutical industry addressing the need for new markers and new drugs within the traditional regulatory frameworks

Friday, September 19, 2014

Aging Forum Program and Information Package

SCHEDULE UPDATE: SEPTEMBER 19TH

PLEASE UPDATE YOUR SCHEDULES



Meeting Location:
Congress Center Basel, MipTec Conference, Scientific Forums

Room 2
Day 1: Tuesday, September 23, 2014, Room 2
08:45-09:00
Introduction to Forum and Day 1

Forum chairs: Alex Zhavoronkov, PhD, Bhupinder Bhullar, PhD
Keynotes and Hallmarks of Aging Research
09:00 - 09:20
Advances in aging biomarkers and drugs with geroprotective properties

Brian Kennedy PhD, Director, CEO, Buck Institute for Aging Research
09:20 - 09:40
New approaches in aging diagnostics

Charles Cantor PhD, Professor, Boston University
09:40 - 10:00
The example of the discovery and development of of mitochondrial derived peptides to delay aging

Nir Barzilai, Director, Albert Einstein College of Medicine
10:00-10.20
Effects of mTOR Inhibition on Immunosenescence  in Elderly Humans

Joan Mannick, MD, Director, Translational Medicine, Novartis Institute for Biomedical Research
10:20-10:40
Break
Session I: Predicting the activity of geroprotective drugs: in-silico screening, omics data analysis and rational drug design
Session Chair: Joao Pedro Megalhaes, PhD
10:40 - 11:00
Novel methods for selecting targeted drugs for personalized medicine in oncology

Anton Buzdin, PhD, DSc, President, CEO, Pathway Pharmaceuticals, Hong Kong
11:00 - 11:20
Bioinformatic analysis of the “omics” data from long-lived animals for geroprotector discovery

Joao Pedro De Magalhaes, PhD, Lab Head, University of Liverpool
11:20 - 11:40
In silico screening for novel drugs with geroprotective properties

Alexander Zhavoronkov, PhD, Director, The Biogerontology Research Foundation, CEO, Insilico Medicine, Inc
11:40 - 12:00
Using novel isotopically-fortified organic compounds to slow down aging processes and treat aging-related diseases

Charles Cator, PhD (on behalf of Robert Molinari, PhD, CEO, Retrotope, Inc)
12:00 -13:30
Lunch and Industry symposia
Room 5
Keynote address: R&D productivity: revival or further decline?
13:30 - 14:15
Dr. Joerg Reinhardt, Chairman of the Board of Directors, Novartis


Session II: Drugs with the potential geroprotective properties
Session Chair: Alexey Moskalev, PhD, DSc
14:30-14:40
Introduction to Session II

Bhupinder Bhullar, PhD
14:40 - 15:00
Advances in the Advanced Glycation Endproduct (AGE) breakers

William Bains, PhD, Head of the SENS Laboratory, Cambridge
15:00 - 15:20
Overview of the possible geroprotectors

Sven Bulterijs, PhD, Post-grad researcher, Yale University
15:20 - 15:40
Applied Epigenetics of Aging and Longevity

Olga Kovalchuk, PhD, Professor, Lab Head, University of Lethbridge, Director, Canada Cancer and Aging Research Laboratories
15:40-16:00
Break
16:00 - 17:00
Roundtable Discussion: How can Pharma engage in aging research?

Moderator: Alex Zhavoronkov, PhD


Day 2: Wednesday, September 24, 2014
08:45 - 09:00
Introduction to Forum and Day 2

Forum Chairs: Alex Zhavoronkov, PhD, Bhupinder Bhullar, PhD
Keynotes and Hallmarks of Aging Research
09:00 - 09:20
Rapamycin and other geroprotectors

Mikhail Blagosklonny, MD, PhD, Professor, Editor-in-Chief of Aging, Cell Cylcle and Oncotarget high-impact journals, Rosewell Park, NY
09:20 - 09:40
The role of Indy in fly health and longevity

Blanka Rogina, PhD, Director Genetics & Developmental Biology Graduate Program, University of Connecticut
09:40 - 10:00
Translating Advances from the Basic Biology of Aging into Clinical Application: Opportunities and Challenges

James Kirkland, MD, PhD, Professor, Mayo Clinic
10:00 - 10:20
How to Solve Genetic Disease on a Population Scale

Barry Merriman, PhD, Professor, UCLA / Lead System Architect, CSO, Thermo Fisher Scientific
10:20 - 10:40
Coffee Break
Session III: Aging Biomarkers: how do we measure aging and geroprotective efficacy
Session Chair: Alexander Bürkle, PhD
10:40 - 11:00
Lessons learned from the EU FP7 MARKAGE Project

Alexander Bürkle, PhD, Professor, EU MARK-AGE Co-ordinator, University of Konstanz
11:00 - 11:20
Comparative genomics of aging and longevity

Vadim Gladyshev, PhD, Professor, Department of Medicine, Harvard Medical School, Director of Redox Medicine, Medicine, Brigham And Women's Hospital, Harvard
11:20 - 11:40
Gene expression patterns in progeria, age-related macular degeneration (AMD) and other age-related diseases

Antonei Benjamin Csoka, PhD, Assoc. Professor, Howard University, CEO, Vision Genomics, Inc
11:40 - 12:00
Experimental approaches to screening of aging-suppressive drugs

Alexey Moskalev, PhD, DSc, Professor, head of the laboratory Moscow Institute of Physics and Technology
12:00 - 13:30
Lunch and Industry Symposia
Room 5
Keynote Address: TBD
13:30 - 14:15
 Dr. Patrick Aebischer,  President Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
Session IV: Trends in Aging Research for Drug Discovery
Session Chair: Richard Faragher, PhD
14.30 - 15:00
Pharmacological prospects for health span extension

Richard Faragher, Professor, University of Brighton
15:00-15:30
Ageing Research and Regenerative Medicine Industry Outlook

Geoffrey Furlonger, CEO, Aging Analytics, Charles Groome, Head of Communications, Aging Analytics UK
15:30 - 16:00
Big Data in Biomedicine: Applying machine learning to predict the outcomes of biomedical research projects

Dmitry Kaminskiy, Director, Senior Partner, Deep Knowledge Ventures
16:00 - 16:20
Coffee Break
16:20 - 16:40
Trends in aging research policy: past, present and future

Dan Perry, CEO, Alliance for Aging Research, USA
16:40-17:00
Concluding remarks and follow up publications

Bhupinder Bhullar, PhD, Director, Novartis; Alex Zhavoronkov, PhD, CEO, Insilico Medicine, Inc

Saturday, September 13, 2014

IMPORTANT: FORUM SCHEDULE UPDATE


Meeting Location:
Congress Center Basel, MipTec Conference, Scientific Forums

Room 2
Day 1: Tuesday, September 23, 2014, Room 2
08:45-09:00
Introduction to Forum and Day 1

Forum chairs: Alex Zhavoronkov, PhD, Bhupinder Bhullar, PhD
Keynotes and Hallmarks of Aging Research
09:00 - 09:20
Advances in aging biomarkers and drugs with geroprotective properties

Brian Kennedy PhD, Director, CEO, Buck Institute for Aging Research
09:20 - 09:40
New approaches in aging diagnostics and interventions

Charles Cantor PhD, Professor, Boston University
09:40 - 10:00
TBD

Nir Barzilai, Director, Albert Einstein College of Medicine
10:00-10.20
Effects of mTOR Inhibition
on Immunosenescence  in Elderly Humans

Joan Mannick, PhD, Director, Translational Medicine, Novartis Institute for Biomedical Research
10:20-10:40
Break
Session I: Predicting the activity of geroprotective drugs: in-silico screening, omics data analysis and rational drug design
Session Chair: Joao Pedro Megalhaes, PhD
10:40 - 11:00
Novel methods for selecting targeted drugs for personalized medicine in oncology

Anton Buzdin, PhD, DSc, President, CEO, Pathway Pharmaceuticals, Hong Kong
11:00 - 11:20
Bioinformatic analysis of the “omics” data from long-lived animals for geroprotector discovery

Joao Pedro De Magalhaes, PhD, Lab Head, University of Liverpool
11:20 - 11:40
In silico screening for novel drugs with geroprotective properties

Alexander Zhavoronkov, PhD, Director, The Biogerontology Research Foundation, CEO, Insilico Medicine, Inc
11:40 - 12:00
Using novel isotopically-fortified organic compounds to slow down the aging processes and treat age related diseases

Robert Molinari, PhD, CEO, Retrotope, Inc
12:00 -13:30
Lunch and Industry symposia
Room 5
Keynote address: R&D productivity: revival or further decline?
13:30 - 14:15
Dr. Joerg Reinhardt, Chairman of the Board of Directors, Novartis


Session II: Drugs with the potential geroprotective properties
Session Chair: Alexey Moskalev, PhD, DSc
14:30-14:40
Introduction to Session II

Bhupinder Bhullar, PhD
14:40 - 15:00
Advances in the Advanced Glycation Endproduct (AGE) breakers

William Bains, PhD, Head of the SENS Laboratory, Cambridge
15:00 - 15:20
Overview of the possible geroprotectors

Sven Bulterijs, PhD, Post-grad researcher, Yale University
15:20 - 15:40
Applied Epigenetics of Aging and Longevity

Olga Kovalchuk, PhD, Professor, Lab Head, University of Lethbridge, Director, Canada Cancer and Aging Research Laboratories
15:40-16:00
Break
16:00 - 17:00
Roundtable Discussion: How can Pharma engage in aging research?

Moderator: Alex Zhavoronkov, PhD


Day 2: Wednesday, September 24, 2014
08:45 - 09:00
Introduction to Forum and Day 2

Forum Chairs: Alex Zhavoronkov, PhD, Bhupinder Bhullar, PhD
Keynotes and Hallmarks of Aging Research
09:00 - 09:20
Rapamycin and other geroprotectors

Mikhail Blagosklonny, MD, PhD, Professor, Editor-in-Chief of Aging, Cell Cylcle and Oncotarget high-impact journals, Rosewell Park, NY
09:20 - 09:40
TBD

Blanka Rogina, PhD, Director Genetics & Developmental Biology Graduate Program, University of Connecticut
09:40 - 10:00
TBD

James Kirkland, MD, PhD, Professor, Mayo Clinic
10:00 - 10:20
How to Solve Genetic Disease on a Population Scale

Barry Merriman, PhD, Professor, UCLA / Lead System Architect, CSO, Thermo Fisher Scientific
10:20 - 10:40
Coffee Break
Session III: Aging Biomarkers: how do we measure aging and geroprotective efficacy
Session Chair: Alexander Bürkle, PhD
10:40 - 11:00
Lessons learned from the EU FP7 MARKAGE Project

Alexander Bürkle, PhD, Professor, EU MARK-AGE Co-ordinator, University of Konstanz
11:00 - 11:20
Comparative genomics of aging and longevity

Vadim Gladyshev, PhD, Professor, Department of Medicine, Harvard Medical School, Director of Redox Medicine, Medicine, Brigham And Women's Hospital, Harvard
11:20 - 11:40
Gene expression patterns in progeria, age-related macular degeneration (AMD) and other age-related diseases

Antonei Benjamin Csoka, PhD, Assoc. Professor, Howard University, CEO, Vision Genomics, Inc
11:40 - 12:00
Genetic and Epigenetic Biomarkers of Aging

Alexey Moskalev, PhD, DSc, Professor, head of the laboratory Moscow Institute of Physics and Technology
12:00 - 13:30
Lunch and Industry Symposia
Room 5
Keynote Address: TBD
13:30 - 14:15
 Dr. Patrick Aebischer,  President Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
Session IV: Trends in Aging Research for Drug Discovery
Session Chair: Richard Faragher, PhD
14.30 - 15:00
Pharmacological prospects for health span extension

Richard Faragher, Professor, University of Brighton
15:00-15:30
Ageing Research and Regenerative Medicine Industry Outlook

Geoffrey Furlonger, CEO, Aging Analytics, Charles Groome, Head of Communications, Aging Analytics UK
15:30 - 16:00
Big Data in Biomedicine: Applying machine learning to predict the outcomes of biomedical research projects

Dmitry Kaminskiy, Director, Senior Partner, Deep Knowledge Ventures
16:00 - 16:20
Coffee Break
16:20 - 16:40
Industry Partnerships for Ageing Research

David Brindley, Research Fellow , Harvard / University of Oxford
16:40-17:00
Concluding remarks